MicroRNA analysis of childhood atopic dermatitis reveals a role for miR-451a.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
accepted:
25
05
2020
pubmed:
2
6
2020
medline:
3
6
2021
entrez:
2
6
2020
Statut:
ppublish
Résumé
MicroRNAs (miRNAs), important regulators of gene expression, have been implicated in a variety of disorders. The expression pattern of miRNAs in paediatric atopic dermatitis (AD) has not been well studied. We sought to investigate miRNA expression profiles in different blood compartments of infants with AD. Small RNA and analysis with the HTG EdgeSeq system were performed to identify differentially expressed miRNAs in peripheral blood mononuclear cells (PBMCs) and plasma of infants with AD vs. age-matched healthy controls, with reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) used for validation and measurement of miRNA targets. Logistic regression models with area under the receiving operating characteristic estimation was used to evaluate the diagnostic potential of chosen miRNAs for AD. RNA sequencing was performed to access miRNA expression profiles in paediatric AD. We identified 10 differentially expressed miRNAs in PBMCs and eight dysregulated miRNAs in plasma of infants with AD compared with controls. Upregulated miRNAs in PBMCs included miRNAs known to be involved in inflammation: miR-223-3p, miR-126-5p and miR-143-3p. Differential expression of only one miRNA, miR-451a, was observed in both PBMCs and plasma of children with AD. Dysregulation of three miRNAs (miR-451a, miR-143-3p and miR-223-3p) was validated in larger numbers of samples and miR-451a was identified as a predictive biomarker for the early diagnosis of the disease. Experimentally verified targets of miR-451a, interleukin 6 receptor (IL6R) and proteasome subunit beta type-8 (PSMB8), were increased in patients with AD, negatively correlated with miR-451a levels and upregulated following inhibition of miR-451a in PBMCs. In infants with AD, a distinct peripheral blood miRNA signature is seen, highlighting the systemic effects of the disease. miR-451a is uniquely expressed in different blood compartments of patients with AD and may serve as a promising novel biomarker for the early diagnosis of AD.
Sections du résumé
BACKGROUND
MicroRNAs (miRNAs), important regulators of gene expression, have been implicated in a variety of disorders. The expression pattern of miRNAs in paediatric atopic dermatitis (AD) has not been well studied.
OBJECTIVES
We sought to investigate miRNA expression profiles in different blood compartments of infants with AD.
METHODS
Small RNA and analysis with the HTG EdgeSeq system were performed to identify differentially expressed miRNAs in peripheral blood mononuclear cells (PBMCs) and plasma of infants with AD vs. age-matched healthy controls, with reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) used for validation and measurement of miRNA targets. Logistic regression models with area under the receiving operating characteristic estimation was used to evaluate the diagnostic potential of chosen miRNAs for AD.
RESULTS
RNA sequencing was performed to access miRNA expression profiles in paediatric AD. We identified 10 differentially expressed miRNAs in PBMCs and eight dysregulated miRNAs in plasma of infants with AD compared with controls. Upregulated miRNAs in PBMCs included miRNAs known to be involved in inflammation: miR-223-3p, miR-126-5p and miR-143-3p. Differential expression of only one miRNA, miR-451a, was observed in both PBMCs and plasma of children with AD. Dysregulation of three miRNAs (miR-451a, miR-143-3p and miR-223-3p) was validated in larger numbers of samples and miR-451a was identified as a predictive biomarker for the early diagnosis of the disease. Experimentally verified targets of miR-451a, interleukin 6 receptor (IL6R) and proteasome subunit beta type-8 (PSMB8), were increased in patients with AD, negatively correlated with miR-451a levels and upregulated following inhibition of miR-451a in PBMCs.
CONCLUSIONS
In infants with AD, a distinct peripheral blood miRNA signature is seen, highlighting the systemic effects of the disease. miR-451a is uniquely expressed in different blood compartments of patients with AD and may serve as a promising novel biomarker for the early diagnosis of AD.
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
514-523Subventions
Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/P00217X/1
Pays : United Kingdom
Organisme : National Children's Research Centre, Dublin
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 British Association of Dermatologists.
Références
Weidinger S, Beck LA, Bieber T et al. Atopic dermatitis. Nat Rev Dis Primers 2018; 4:1.
Bieber T. Atopic dermatitis. N Engl J Med 2008; 358:1483-94.
Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387:1109-22.
Paternoster L, Standl M, Waage J et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet 2015; 47:1449-56.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97.
Kuersten S, Goodwin EB. The power of the 3′ UTR: translational control and development. Nat Rev Genet 2003; 4:626-37.
Baek D, Villen J, Shin C et al. The impact of microRNAs on protein output. Nature 2008; 455:64-71.
Rebane A, Runnel T, Aab A et al. MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. J Allergy Clin Immunol 2014; 134:836-847 e11.
Sonkoly E, Janson P, Majuri ML et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol 2010; 126:581-589 e1-20.
Brunner PM, Israel A, Zhang N et al. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol 2018; 141:2094-106.
Esaki H, Brunner PM, Renert-Yuval Y et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol 2016; 138:1639-51.
Lv Y, Qi R, Xu J et al. Profiling of serum and urinary microRNAs in children with atopic dermatitis. PLoS One 2014; 9:e115448.
Turchinovich A, Cho WC. The origin, function and diagnostic potential of extracellular microRNA in human body fluids. Front Genet 2014; 5:30.
Cammarata G, Scalia S, Colomba P et al. A pilot study of circulating microRNAs as potential biomarkers of Fabry disease. Oncotarget 2018; 9:27333-45.
Jamali L, Tofigh R, Tutunchi S et al. Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J Cell Physiol 2018; 233:8538-50.
Panganiban RP, Wang Y, Howrylak J et al. Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 2016; 137:1423-32.
Pritchard CC, Kroh E, Wood B et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012; 5:492-7.
Ioannidis J, Donadeu FX. Comprehensive analysis of blood cells and plasma identifies tissue-specific miRNAs as potential novel circulating biomarkers in cattle. BMC Genomics 2018; 19:243.
Williams Z, Ben-Dov IZ, Elias R et al. Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. Proc Natl Acad Sci U S A 2013; 110:4255-60.
Han L, Vickers KC, Samuels DC et al. Alternative applications for distinct RNA sequencing strategies. Brief Bioinform 2015; 16:629-39.
Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012; 13:358-69.
Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10:57-63.
McAleer MA, Jakasa I, Hurault G et al. Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis. Br J Dermatol 2019; 180:586-96.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402-8.
Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res 2015; 43:D146-52.
Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015; 4:e05005.
John B, Enright AJ, Aravin A et al. Human microRNA targets. PLoS Biol 2004; 2:e363.
Karagkouni D, Paraskevopoulou MD, Chatzopoulos S et al. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. Nucleic Acids Res 2018; 46:D239-45.
Chou CH, Shrestha S, Yang CD et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res 2018; 46:D296-302.
Vlachos IS, Zagganas K, Paraskevopoulou MD et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res 2015; 43:W460-6.
da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57.
Zhou W, Pal AS, Hsu AY et al. MicroRNA-223 suppresses the canonical NF-kappaB pathway in basal keratinocytes to dampen neutrophilic inflammation. Cell Rep 2018; 22:1810-23.
Lovendorf MB, Zibert JR, Gyldenlove M et al. MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. J Dermatol Sci 2014; 75:133-9.
Mattes J, Collison A, Plank M et al. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci U S A 2009; 106:18704-9.
Guo H, Nan Y, Zhen Y et al. miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1. Tumour Biol 2016; 37:13751-61.
Liu X, Zhang A, Xiang J et al. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway. Oncol Rep 2016; 36:1385-92.
Wang H, Zhang G, Wu Z et al. MicoRNA-451 is a novel tumor suppressor via targeting C-Myc in head and neck squamous cell carcinomas. J Cancer Res Ther 2015; 11 (Suppl. 2):C216-21.
Patrick DM, Zhang CC, Tao Y et al. Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zeta. Genes Dev 2010; 24:1614-19.
Kent OA, McCall MN, Cornish TC et al. Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res 2014; 42:7528-38.
Murata K, Yoshitomi H, Furu M et al. MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK. Arthritis Rheumatol 2014; 66:549-59.
Rosenberger CM, Podyminogin RL, Navarro G et al. miR-451 regulates dendritic cell cytokine responses to influenza infection. J Immunol 2012; 189:5965-75.
Zeng Z, Wang K, Li Y et al. Down-regulation of microRNA-451a facilitates the activation and proliferation of CD4(+) T cells by targeting Myc in patients with dilated cardiomyopathy. J Biol Chem 2017; 292:6004-13.
Li HP, Zeng XC, Zhang B et al. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-beta. Carcinogenesis 2013; 34:2443-51.
Zeng T, Peng L, Chao C et al. miR-451 inhibits invasion and proliferation of bladder cancer by regulating EMT. Int J Clin Exp Pathol 2014; 7:7653-62.
Sun Y, Peng R, Peng H et al. miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy. Mol Cell Endocrinol 2016; 433:75-86.
Zhang X, Wang X, Zhu H et al. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J Mol Cell Cardiol 2010; 49:841-50.
Cantoni C, Cignarella F, Ghezzi L et al. Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathol 2017; 133:61-77.
Lam J, van den Bosch M, Wegrzyn J et al. miR-143/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGFbeta signaling. Nat Commun 2018; 9:2418.
Lovendorf MB, Mitsui H, Zibert JR et al. Laser capture microdissection followed by next-generation sequencing identifies disease-related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis. Exp Dermatol 2015; 24:187-93.
Yin P, Peng R, Peng H et al. MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells. Mol Biotechnol 2015; 57:1-11.
Kimura H, Caturegli P, Takahashi M et al. New insights into the function of the immunoproteasome in immune and nonimmune cells. J Immunol Res 2015; 2015:541984.
Agarwal AK, Xing C, DeMartino GN et al. PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 2010; 87:866-72.
Arima K, Kinoshita A, Mishima H et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A 2011; 108:14914-19.
Kitamura A, Maekawa Y, Uehara H et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest 2011; 121:4150-60.
Esparza-Gordillo J, Schaarschmidt H, Liang L et al. A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis. J Allergy Clin Immunol 2013; 132:371-7.
Ferreira MA, Matheson MC, Duffy DL et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet 2011; 378:1006-14.
Marinou I, Walters K, Winfield J et al. A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility. Ann Rheum Dis 2010; 69:1191-4.
Navarini AA, French LE, Hofbauer GF. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 2011; 128:1128-30.